ATE465266T1 - Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren - Google Patents

Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren

Info

Publication number
ATE465266T1
ATE465266T1 AT99966715T AT99966715T ATE465266T1 AT E465266 T1 ATE465266 T1 AT E465266T1 AT 99966715 T AT99966715 T AT 99966715T AT 99966715 T AT99966715 T AT 99966715T AT E465266 T1 ATE465266 T1 AT E465266T1
Authority
AT
Austria
Prior art keywords
alphavirus
vectors
packaging
nucleic acid
methods
Prior art date
Application number
AT99966715T
Other languages
English (en)
Inventor
John Polo
Barbara Belli
Thomas Dubensky
Stephen Hardy
Perri Silvia
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE465266T1 publication Critical patent/ATE465266T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • C12N2770/36152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Packages (AREA)
  • Wrappers (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Laminated Bodies (AREA)
AT99966715T 1998-12-31 1999-12-30 Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren ATE465266T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11473298P 1998-12-31 1998-12-31
PCT/US1999/031193 WO2000039318A1 (en) 1998-12-31 1999-12-30 Compositions and methods for packaging of alphavirus vectors

Publications (1)

Publication Number Publication Date
ATE465266T1 true ATE465266T1 (de) 2010-05-15

Family

ID=22357098

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99966715T ATE465266T1 (de) 1998-12-31 1999-12-30 Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren

Country Status (7)

Country Link
US (1) US6242259B1 (de)
EP (1) EP1141361B1 (de)
AT (1) ATE465266T1 (de)
AU (1) AU2220800A (de)
CA (1) CA2359013C (de)
DE (1) DE69942280D1 (de)
WO (1) WO2000039318A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6844188B1 (en) 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
US6423544B1 (en) * 1998-12-31 2002-07-23 Chiron Corporation Compositions and methods for producing recombinant virions
US6329201B1 (en) * 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
EP1035205A1 (de) * 1999-03-08 2000-09-13 Stichting Dienst Landbouwkundig Onderzoek Sich nicht verbreitendes Pestivirus
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
US6982087B2 (en) * 2000-09-07 2006-01-03 The University Of North Carolina At Chapel Hill Vectors derived from South African Arbovirus No. 86
WO2002062949A2 (en) 2000-10-20 2002-08-15 Canji, Inc Aptamer-mediated regulation of gene expression
CN1520303B (zh) * 2001-03-27 2013-04-24 纽约大学 利用基于α病毒且靶向高亲和性层粘连蛋白受体的载体进行肿瘤治疗
ES2345876T3 (es) 2001-05-31 2010-10-05 Novartis Vaccines And Diagnostics, Inc. Particulas de replicones de alfavirus quimericos.
US7045335B2 (en) * 2001-09-06 2006-05-16 Alphavax, Inc. Alphavirus replicon vector systems
WO2003029492A1 (en) * 2001-09-28 2003-04-10 Justin Gallivan Metabolic genes and related methods and compositions
US20050215472A1 (en) * 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP3184539A3 (de) * 2001-10-23 2017-09-13 PSMA Development Company L.L.C. Psma antikörper
AU2003282538A1 (en) * 2002-10-10 2004-05-04 Oxford Biomedica (Uk) Limited Gene regulation with aptamer and modulator complexes for gene therapy
CA2509973C (en) 2002-12-13 2013-02-26 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
DK3246399T3 (da) 2002-12-13 2021-10-04 Alphavax Inc Alfavirus-partikler og fremgangsmåder til fremstilling
KR101454842B1 (ko) * 2003-03-20 2014-11-04 알파벡스, 인크. 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
PT1651666E (pt) * 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
US7910093B2 (en) 2003-08-19 2011-03-22 New York University Method for detecting cancer cells and monitoring cancer therapy
DE602005012382D1 (de) 2004-05-18 2009-03-05 Alphavax Inc Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
JP4896021B2 (ja) 2004-05-21 2012-03-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 呼吸器系病原体ワクチンのためのアルファウイルスベクター
WO2006085983A2 (en) 2004-07-09 2006-08-17 University Of North Carolina At Chapel Hill Viral adjuvants
US20060198854A1 (en) * 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
CA2597921A1 (en) * 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines
EP2535355B1 (de) 2005-03-23 2019-01-02 Genmab A/S Antikörper gegen CD38 zur Behandlung von multiplem Myelom
US7303898B2 (en) * 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
JP2009511636A (ja) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
WO2008085557A2 (en) 2006-09-12 2008-07-17 Alphavax, Inc. Alphavirus replicon particles encoding il- 12 as immunological adjuvants
ES2517869T3 (es) 2006-09-12 2014-11-04 Alphavax, Inc. Partículas de replicones de alfavirus emparejadas con antígenos proteicos como adyuvantes inmunológicos
ES2673823T3 (es) * 2006-11-03 2018-06-25 Alphavax, Inc. Formulaciones de alfavirus y de partículas de replicones de alfavirus y métodos relacionados
EP2183368B1 (de) 2007-06-21 2016-08-10 Alphavax, Inc. Promotorenlose kassetten zur expression von alphavirus-strukturproteinen
DK2222697T3 (da) 2007-11-01 2013-03-11 Perseid Therapeutics Llc Immunsuppressive polypeptider og nukleinsyrer
WO2010065414A1 (en) 2008-12-01 2010-06-10 Alphavax, Inc. Use of micrornas to control virus helper nucleic acids
WO2010118244A1 (en) 2009-04-08 2010-10-14 Alphavax, Inc. Alphavirus Replicon Particles Expressing TRP2
US20140093556A1 (en) 2011-01-28 2014-04-03 Sanofi Pasteur Sa Immunological Compositions Against HIV
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
JP2019511255A (ja) 2016-01-11 2019-04-25 バーンダリ，インク． マイクロニードル組成物およびそれを使用する方法
NL2022538B1 (en) 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
JP4383530B2 (ja) 1996-04-05 2009-12-16 ノバルティス バクシンズ アンド ダイアグノスティックス， インコーポレーテッド 細胞巨大分子合成の阻害が減少したアルファウイルスベクター

Also Published As

Publication number Publication date
DE69942280D1 (de) 2010-06-02
CA2359013C (en) 2011-02-01
CA2359013A1 (en) 2000-07-06
EP1141361A1 (de) 2001-10-10
AU2220800A (en) 2000-07-31
EP1141361B1 (de) 2010-04-21
US6242259B1 (en) 2001-06-05
WO2000039318A1 (en) 2000-07-06

Similar Documents

Publication Publication Date Title
ATE465266T1 (de) Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren
ATE443074T1 (de) Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
DE69834908D1 (de) Verfahren zur erhöhung der expression von endogenen oder exogenen genprodukten in pflanzen
ZA967173B (en) Purified coprinus laccases and nucleic acids and encoding same
DE69738521D1 (de) Alphaviren-vektors mit eine reduzierte inhibierung der synthese von zellmakromolekülen
ATE312176T1 (de) Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien
CA2400295A1 (en) Modified factor viii
ATE447583T1 (de) Polypeptide und dafür kodierende nukleinsäure
WO1999011764A3 (en) Methods for generating high titer helper-free preparations of recombinant aav vectors
ATE444361T1 (de) Il-17 und il-17r homologe polypeptide und deren therapeutische verwendungen
ES2170622A1 (es) Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
ATE384787T1 (de) Tripeptidyl-aminopeptidase
DE60141014D1 (de) Verfharen zur herstellung von herpes-simplex-virus-amplikons, die resultierenden amplikons und ihre verwendung
DE69504808D1 (de) Corticotropin freisetzende rezeptoren des faktor 2
DK1082423T3 (da) Cyclin E2-gener og -proteiner
CA2390049A1 (en) Control of post-transcriptional gene silencing in plants
DE60117998D1 (de) Mutierte furin polypeptide, welche verbesserte eigenschaften aufweisen
DE69619808T2 (de) Chimäre msp und daf proteine mit einem telloberflächenlokalisierendem domän
ATE288488T1 (de) Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen
WO2000044898A3 (en) Novel agouti and agouti-related peptide analogs
DE60011464D1 (de) Herstellung von heterloge proteine
ATE318920T1 (de) Promotoren zur genexpression in karyopsen von pflanzen
DK0870050T3 (da) Virus, der udtrykker et toksisk protein, og producercellelinier
WO2000026340A3 (en) Novel nucleic acid molecules encoding opioid growth factor receptors
HK1120077A1 (en) Neutrokine-alpha and neutrokine-alpha splice variant neutrokine-

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1141361

Country of ref document: EP